Filing Flows › Coherus Oncology (CHRS) › Q4 2025
Coherus Oncology (CHRS) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 9, 2026
Coherus Oncology (CHRS) reported revenue of $12.7M for the fourth quarter 2025 (Q4 2025), +65% from a year earlier and +10% from the quarter before. Operating margin was -359.9%, net loss $37.6M (295.3% of revenue).
Coherus Oncology, Q4 2025: revenue $12.7M (+65% year over year), operating margin -359.9%, net loss $37.6M, operating cash flow −$19.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.7M | +10% | +65% |
| Operating profit | −$45.9M | — | — |
| Net earnings | −$37.6M | — | — |
| Operating cash flow | −$19.7M | — | -169% |
What changed
Revenue was $12.7M in Q4 2025, up 65% year over year and up 10% from the previous quarter. Toripalimab was the largest line at 97% of revenue.
Operating costs exceeded revenue by $45.9M, an operating margin of -359.9%. Total costs grew 10% against revenue growth of 65%. The fastest-growing cost line was Research & development (+49%). The quarter ended with a net loss of $37.6M, wider than the previous quarter's $35.5M loss.
Operating cash flow was −$19.7M. Non-cash charges added back $300K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items added $14.8M.
Questions
What was Coherus Oncology's revenue in the fourth quarter 2025?
Coherus Oncology (CHRS) reported revenue of $12.7M for the fourth quarter 2025 (Q4 2025), +65% from a year earlier and +10% from the quarter before.
Was Coherus Oncology profitable in the fourth quarter 2025?
Operating loss was $45.9M (-359.9% of revenue) and net loss $37.6M.
Source: Coherus Oncology 10-K on SEC EDGAR.